Next Article in Journal
PI3K and AKT: Unfaithful Partners in Cancer
Next Article in Special Issue
Isolation of Specific Genomic Regions and Identification of Their Associated Molecules by Engineered DNA-Binding Molecule-Mediated Chromatin Immunoprecipitation (enChIP) Using the CRISPR System and TAL Proteins
Previous Article in Journal
Phytochemical Characterization of Veronica officinalis L., V. teucrium L. and V. orchidea Crantz from Romania and Their Antioxidant and Antimicrobial Properties
Previous Article in Special Issue
Direct Injection of CRISPR/Cas9-Related mRNA into Cytoplasm of Parthenogenetically Activated Porcine Oocytes Causes Frequent Mosaicism for Indel Mutations
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Single-Base Pair Genome Editing in Human Cells by Using Site-Specific Endonucleases

Research Center for the Mathematics on Chromatin Live Dynamics (RcMcD), Hiroshima University, Higashi-Hiroshima 739-8530, Japan
Int. J. Mol. Sci. 2015, 16(9), 21128-21137; https://doi.org/10.3390/ijms160921128
Submission received: 10 August 2015 / Revised: 27 August 2015 / Accepted: 28 August 2015 / Published: 3 September 2015
(This article belongs to the Special Issue Genome Editing)

Abstract

:
Genome-wide association studies have identified numerous single-nucleotide polymorphisms (SNPs) associated with human diseases or phenotypes. However, causal relationships between most SNPs and the associated disease have not been established, owing to technical challenges such as unavailability of suitable cell lines. Recently, efficient editing of a single base pair in the genome was achieved using programmable site-specific nucleases. This technique enables experimental confirmation of the causality between SNPs and disease, and is potentially valuable in clinical applications. In this review, I introduce the molecular basis and describe examples of single-base pair editing in human cells. I also discuss the challenges associated with the technique, as well as possible solutions.

1. Introduction

Programmable nucleases, including zinc-finger nucleases (ZFNs), transcription activator like-effector nucleases (TALENs), and Clustered Regulatory Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated 9 (Cas9), may be used to engineer double-strand breaks (DSBs) in the genome. By then exploiting the endogenous DSB repair pathway in cells, genomes can be edited to disrupt, introduce, invert, delete, or correct genes [1]. Genome editing with ZFNs and TALENs initially attracted much attention, but was not widely adopted because of the complexity in designing these enzymes. The introduction of CRISPR/Cas9 in 2013 [2,3] has dramatically changed life science research in many ways [4], because the system is significantly easier to implement. Genome editing is now used in medical research to, for example, identify causal mutations underlying inherited disorders [5], establish disease models via induced pluripotent stem (iPS) cells [6], and treat human immunodeficiency virus infection or acquired immune deficiency syndrome [7].
Genome-wide association studies have identified a large number of single-nucleotide polymorphisms (SNPs) associated with human disorders and with physical traits such as height, olfactory sensitivity, and skin color [8]. SNPs in coding regions or splice sites that are predicted to drastically change protein structure or function are suspected, with good reason, to underlie the associated disorder or trait. In these instances, functional analysis of the SNP is relatively straightforward. However, SNPs that are intergenic or non-coding are not as easily characterized [9]. On the other hand, high-throughput DNA sequencing has enabled identification of actively regulated regions that are enriched in specific histone modifications, transcription factor binding sites, or DNase-hypersensitive sites [10]. SNPs within these putative regulatory sequences, aptly named regulatory SNPs, are expected to reliably produce the observed phenotypes [9,11,12]. Nevertheless, experimental characterization of these SNPs remains challenging [13]. This situation is especially true of single-nucleotide variations strongly associated with rare disorders.
One of the most straightforward methods to characterize SNPs, single-nucleotide variations, or major allelic variants is to engineer them directly into the genome. Unfortunately, single-base pair editing through spontaneous homologous recombination is impractical or unachievable. Therefore, efficient, site-specific genome-editing technologies based on programmable nucleases are required [14]. Seamless genome editing, in which target nucleotides are mutated without further footprint, is also critical, especially in regenerative medicine [15]. Importantly, the efficiency of seamless genome editing largely depends on the system and technique used.
In this review, I will focus on single-base pair editing and related techniques, especially those used for seamless genome editing in human cells. I will also examine the merits and demerits of each technique, and explore potential technical improvements.

2. Seamless Single-Base Pair Editing and Related Techniques

Seamless single-base pair editing and related techniques require highly site-specific programmable nucleases, and exploit homology-directed repair (HDR), one of two major endogenous DSB repair pathways (Figure 1). These techniques are categorized into two classes based on whether selection markers are used.
Figure 1. Single-base pair genome editing and related techniques. Schematic representation of methods to engineer a single or a small number of nucleotide substitutions into the genome. (A,B) Selection-independent editing of a target base pair within (A) and out (B) of a sequence recognized by a programmable nuclease; (C,D) Selection-dependent editing using different methods to excise the selection marker. piggyBac-excision is illustrated without (C) or with (D) a TTAA sequence naturally present near or at the target site. Blue, gray, red, and green lines represent programmable nuclease target sites with deletions, insertions, single, and multiple nucleotide substitutions, respectively. Target sites with single nucleotide substitutions may be recut by the programmable nuclease depending on the properties of the enzyme and the location of the substitution. Scissors and yellow star shapes represent programmable endonucleases and DNA double-strand breaks (DSBs), respectively.
Figure 1. Single-base pair genome editing and related techniques. Schematic representation of methods to engineer a single or a small number of nucleotide substitutions into the genome. (A,B) Selection-independent editing of a target base pair within (A) and out (B) of a sequence recognized by a programmable nuclease; (C,D) Selection-dependent editing using different methods to excise the selection marker. piggyBac-excision is illustrated without (C) or with (D) a TTAA sequence naturally present near or at the target site. Blue, gray, red, and green lines represent programmable nuclease target sites with deletions, insertions, single, and multiple nucleotide substitutions, respectively. Target sites with single nucleotide substitutions may be recut by the programmable nuclease depending on the properties of the enzyme and the location of the substitution. Scissors and yellow star shapes represent programmable endonucleases and DNA double-strand breaks (DSBs), respectively.
Ijms 16 21128 g001
In selection-independent genome editing, only the intended nucleotide substitutions are directly engineered into the target site via a DSB and a template that consists of either plasmids or single-stranded oligodeoxynucleotides (ssODNs) (Figure 1A,B, and Table 1). However, HDR is less frequently activated in cells than non-homologous end joining (NHEJ), the other major DSB repair pathway, which is error-prone and frequently introduces additional deletions and insertions. Therefore, appropriate methods are required to identify cells with only the desired nucleotide changes (Figure 1).
On the other hand, selection-dependent methods require two rounds of genome editing (Figure 1C,D, and Table 2). In the first round, a plasmid vector is used to knock nucleotide substitutions into the target site, along with selection markers. These selection markers are then excised in the subsequent round (Figure 1C,D). While this method seems more labor-intensive, it is also more efficient and reliable.
Table 1. Selection-independent seamless genome editing.
Table 1. Selection-independent seamless genome editing.
Programmable NucleaseHost CellTargetTemplateEdits IntroducedReference
ZFNK562IL2Rγplasmid1 bp substitution[14]
CD4+ T
ZFNK562RSK2ssODNSubstitution of 6 bp in and out of ZFN recognition site[16]
ZFNESSNCAssODN1 bp substitution[17]
iPSplasmid
TALENiPSCCR5ssODN2 bp substitutions[18]
CRISPR
TALENiPSAKT2ssODN2 bp substitutions[6]
TALENiPSPHOX2BssODN1 bp substitution[19]
PRKAG2
Table 2. Selection-dependent seamless genome editing.
Table 2. Selection-dependent seamless genome editing.
Programmable NucleaseExcision MethodHost CellTargetEdits IntroducedReference
ZFNCre/loxPES iPSSNCA1 bp substitution and loxP site insertion[17]
ZFNpiggyBaciPSA1AT1 bp substitution of interest and 2 to generate TTAA site [20]
CRISPRpiggyBaciPSHBB1 bp substitution and 4 bp insertion *[15]
TALENpiggyBaciPSHBB3 bp substitutions[21]
TALENTALENHCT116Interge region (upstream of BUBR1)1 bp substitution[5]
* Two different β-thalassemia mutations (a single nucleotide substitution and a 4 bp deletion) were corrected in two different alleles. Therefore, the correction is a single-base pair edit and a 4-bp insertion in each allele.

2.1. Selection-Independent Methods

Selection-independent methods are straightforward, because nucleotide substitutions are engineered in a single step without the use of selection markers (Figure 1A). In addition, ssODNs may be used as template instead of plasmids [16,17], which could be randomly integrated into the host genome [16]. Nevertheless, the use of highly specific programmable nucleases is critical to minimize recutting and insertion of unintended mutations by NHEJ (Figure 1A,B). ZFNs with high specificity may distinguish a single nucleotide substitution [22]. However, these enzymes are limited in the range of sequences they can target, and, therefore, an appropriate ZFN may not be available for a target base pair [17]. In this case, additional mutations will have to be introduced to inhibit recutting and mutagenesis by NHEJ [16] (Figure 1A). For target sites in coding regions, synonymous mutations that inhibit recutting may not be an issue. However, many SNPs are, as noted, in non-coding regions of unknown function, to which introduction of a neutral substitution is difficult, if not impossible. Unfortunately, preparation of ZFNs with the desired specificity is extremely labor-intensive. As a result, these nucleases are not widely used in academic research [23].
On the other hand, TALENs are much easier to obtain, and are almost unrestricted in targetable sites [24]. These sites are relatively long (~17 bp each), and very high specificity can be achieved at unique or sufficiently distinctive targets. However, TALENs, in most cases, cannot distinguish a single nucleotide mismatch. Thus, TALENs are not suitable for seamless genome editing by selection-independent methods [18]. On the other hand, the widely used S. pyogenes Cas9 (SpCas9) has been demonstrated to detect a mismatched nucleotide near or in the protospacer adjacent motif (PAM) [2,25]. Therefore, if the target base pair is located near or in this motif, CRISPR/Cas9 can be useful to seamlessly edit single base pairs without selection.
The identification and isolation of cells with the intended nucleotide changes are a major challenge. In general, exogenous DNA and RNA are not delivered uniformly into individual cells, and some cells are not transduced at all. Conversely, cells receiving a high dose may become unviable [26,27]. To avoid this problem, site-specific endonucleases are delivered at a small dose, along with template DNA and a vector expressing either a drug-resistance protein or green fluorescent protein. Transformed cells are then identified by transient drug selection or fluorescence-activated cell sorting, respectively [6,17,28]. This approach drastically enhances efficiency.
Recently, Miyaoka et al. [19] described an alternative screening method. In this approach, TALEN expression vectors are delivered at low dose to minimize off-target effects. Then, cells are replated into a 96-well plate. After the incubation, cells are split into two replicate cultures, one of which is analyzed by highly sensitive digital PCR for the desired nucleotide substitution. Cells from the remaining replicate well that contains the desired edits are further replated, multiple times if necessary, to purify transformed cells. In the end, a cell line with a single nucleotide substitution is established.

2.2. Selection-Dependent Methods

Although selection-dependent methods are labor-intensive, and require two rounds of editing (Figure 1C,D and Table 2), they may be ultimately more efficient. The intended nucleotide substitution is not always integrated into the genome, and insertion efficiency depends to a significant extent on the distance between the desired mutation and the cut site of the programmable nuclease [29] (Ochiai, data not shown). The use of markers, including puromycin resistance for positive selection and herpes simplex virus thymidine kinase for negative selection, enables efficient selection of cell clones that contain the desired mutations [20]. Thus, nucleotide substitutions of interest are engineered into the target site along with a selection cassette in the first round. To avoid recutting, the selection cassette is typically inserted within the endonuclease target site. In the second round, the selection cassette is excised, usually by the Cre/loxP system [17], by the piggyBac system [15,20,29], or by a programmable nuclease [5].

2.2.1. Cre/loxP-Mediated Excision

The Cre-loxP system is a long-established tool for genetic manipulation, and enables deletions, insertions, translocations, and inversions at specific genomic sites in cells [30]. Therefore, the selection cassette can be easily excised by expression of Cre recombinase if it is flanked by 34-bp loxP sites [17]. However, a loxP site is left behind as a footprint and may confound the effects of the intended substitutions (Figure 1C). Furthermore, the system also has off-target concerns as programmable nucleases [31,32].

2.2.2. piggyBac-Mediated Excision

piggyBac transposons are flanked by piggyBac inverted terminal repeats, and transpose between vectors and chromosomes in a process that requires piggyBac transposase [33,34,35]. Excision of the transposon leaves a TTAA fragment behind, a scar that may, as noted, complicate the interpretation of results (Figure 1C). However, if a TTAA site is naturally present at or near the target site, piggyBac-mediated genome editing is essentially seamless (Figure 1D) [15].

2.2.3. Excision by a Programmable Nuclease

Programmable nucleases may also be used to excise the selection cassette out of the target site. In this method, a secondary targeting vector is required, as well as additional programmable nucleases that will cut sequences that flank the selection cassette (Figure 1C) [5]. Alternatively, secondary ssODNs may also be used instead of secondary plasmids [16]. On the other hand, the need for a secondary vector may be eliminated entirely by adding microhomology sites at both sides of the selection cassette to enable efficient excision via microhomology-mediated DSB repair [36].
Programmable nucleases circumvent the need for a TTAA fragment near the target site, as would be required in piggyBac-mediated excision. However, the need to design these additional programmable nucleases is a drawback, as is the additional risk of off-target effects from such secondary enzymes. The use of CRISPR enzymes instead of ZFNs and TALENs may help reduce the labor required, while off-target effects may be minimized with ZFNs and TALENs that contain heterodimeric nuclease domains [37,38,39] or with Cas9 nickase mutants [40].

3. Conclusions

Genome editing with programmable nucleases enables efficient, seamless substitutions of a single or a small number of nucleotides at predefined sites. However, technical hurdles remain, and prevent widespread adoption. To date, the CRISPR/Cas9 system is the most attractive, for ease of implementation and ability to distinguish a single mismatched nucleotide in or near the PAM sequence. Recently, several Cas9 orthologs from different species have been reported, as well as SpCas9 mutants that recognize an array of PAM sequences [41,42]. Furthermore, the structure of Cas9 has been determined, and I anticipate that Cas9 mutants with diverse PAM sequence specificities will soon be identified or engineered [43,44]. Indeed, single-nucleotide editing with ssODN templates will become highly efficient if programmable nucleases could be engineered to have broad targetable sequences, high specificity, and sensitivity to single-nucleotide mismatches.

Acknowledgments

This research was partly supported by the Platform Project for Supporting in Drug Discovery and Life Science Research (Platform for Dynamic Approaches to Living System) from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT), by the Japan Agency for Medical Research and Development (AMED), by Grants-in-Aid for Scientific Research from MEXT [15K18467], and by the program of the Joint Usage/Research Center for Developmental Medicine, Institute of Molecular Embryology and Genetics, Kumamoto University (Kumamoto, Japan).

Conflicts of Interest

The author declares no conflict of interest.

References

  1. Carroll, D. Genome engineering with targetable nucleases. Annu. Rev. Biochem. 2014, 83, 409–439. [Google Scholar] [CrossRef] [PubMed]
  2. Cong, L.; Ran, F.A.; Cox, D.; Lin, S.; Barretto, R.; Habib, N.; Hsu, P.D.; Wu, X.; Jiang, W.; Marraffini, L.A.; et al. Multiplex genome engineering using CRISPR/Cas systems. Science 2013, 339, 819–823. [Google Scholar] [CrossRef] [PubMed]
  3. Mali, P.; Yang, L.; Esvelt, K.M.; Aach, J.; Guell, M.; DiCarlo, J.E.; Norville, J.E.; Church, G.M. RNA-guided human genome engineering via Cas9. Science 2013, 339, 823–826. [Google Scholar] [CrossRef] [PubMed]
  4. Ledford, H. CRISPR, the disruptor. Nature 2015, 522, 20–24. [Google Scholar] [CrossRef] [PubMed]
  5. Ochiai, H.; Miyamoto, T.; Kanai, A.; Hosoba, K.; Sakuma, T.; Kudo, Y.; Asami, K.; Ogawa, A.; Watanabe, A.; Kajii, T.; et al. TALEN-mediated single-base-pair editing identification of an intergenic mutation upstream of BUB1B as causative of PCS (MVA) syndrome. Proc. Natl. Acad. Sci. USA 2014, 111, 1461–1466. [Google Scholar] [CrossRef] [PubMed]
  6. Ding, Q.; Lee, Y.-K.; Schaefer, E.A.K.; Peters, D.T.; Veres, A.; Kim, K.; Kuperwasser, N.; Motola, D.L.; Meissner, T.B.; Hendriks, W.T.; et al. A TALEN genome-editing system for generating human stem cell-based disease models. Cell Stem Cell 2013, 12, 238–251. [Google Scholar] [CrossRef] [PubMed]
  7. Tebas, P.; Stein, D.; Tang, W.W.; Frank, I.; Wang, S.Q.; Lee, G.; Spratt, S.K.; Surosky, R.T.; Giedlin, M.A.; Nichol, G.; et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N. Engl. J. Med. 2014, 370, 901–910. [Google Scholar] [CrossRef] [PubMed]
  8. Welter, D.; MacArthur, J.; Morales, J.; Burdett, T.; Hall, P.; Junkins, H.; Klemm, A.; Flicek, P.; Manolio, T.; Hindorff, L.; et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res. 2014, 42, D1001–D1006. [Google Scholar] [CrossRef] [PubMed]
  9. Maurano, M.T.; Humbert, R.; Rynes, E.; Thurman, R.E.; Haugen, E.; Wang, H.; Reynolds, A.P.; Sandstrom, R.; Qu, H.; Brody, J.; et al. Systematic Localization of Common Disease-Associated Variation in Regulatory DNA. Science 2012, 337, 1190–1195. [Google Scholar] [CrossRef] [PubMed]
  10. Shlyueva, D.; Stampfel, G.; Stark, A. Transcriptional enhancers: From properties to genome-wide predictions. Nat. Rev. Genet. 2014, 15, 272–286. [Google Scholar] [CrossRef] [PubMed]
  11. Visser, M.; Kayser, M.; Palstra, R.-J. HERC2 rs12913832 modulates human pigmentation by attenuating chromatin-loop formation between a long-range enhancer and the OCA2 promoter. Genome Res. 2012, 22, 446–455. [Google Scholar] [CrossRef] [PubMed]
  12. Ward, L.D.; Kellis, M. Interpreting noncoding genetic variation in complex traits and human disease. Nat. Biotechnol. 2012, 30, 1095–1106. [Google Scholar] [CrossRef] [PubMed]
  13. Musunuru, K.; Strong, A.; Frank-Kamenetsky, M.; Lee, N.E.; Ahfeldt, T.; Sachs, K.V.; Li, X.; Li, H.; Kuperwasser, N.; Ruda, V.M.; et al. From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature 2010, 466, 714–719. [Google Scholar] [CrossRef] [PubMed]
  14. Urnov, F.D.; Miller, J.C.; Lee, Y.-L.; Beausejour, C.M.; Rock, J.M.; Augustus, S.; Jamieson, A.C.; Porteus, M.H.; Gregory, P.D.; Holmes, M.C. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 2005, 435, 646–651. [Google Scholar] [CrossRef] [PubMed]
  15. Xie, F.; Ye, L.; Chang, J.C.; Beyer, A.I.; Wang, J.; Muench, M.O.; Kan, Y.W. Seamless gene correction of β-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac. Genome Res. 2014, 24, 1526–1533. [Google Scholar] [CrossRef] [PubMed]
  16. Chen, F.; Pruett-Miller, S.M.; Huang, Y.; Gjoka, M.; Duda, K.; Taunton, J.; Collingwood, T.N.; Frodin, M.; Davis, G.D. High-frequency genome editing using ssDNA oligonucleotides with zinc-finger nucleases. Nat. Methods 2011, 8, 753–755. [Google Scholar] [CrossRef] [PubMed]
  17. Soldner, F.; Laganière, J.; Cheng, A.W.; Hockemeyer, D.; Gao, Q.; Alagappan, R.; Khurana, V.; Golbe, L.I.; Myers, R.H.; Lindquist, S.; et al. Generation of isogenic pluripotent stem cells differing exclusively at two early onset parkinson point mutations. Cell 2011, 146, 318–331. [Google Scholar] [CrossRef] [PubMed]
  18. Yang, L.; Guell, M.; Byrne, S.; Yang, J.L.; De Los Angeles, A.; Mali, P.; Aach, J.; Kim-Kiselak, C.; Briggs, A.W.; Rios, X.; et al. Optimization of scarless human stem cell genome editing. Nucleic Acids Res. 2013, 41, 9049–9061. [Google Scholar] [CrossRef] [PubMed]
  19. Miyaoka, Y.; Chan, A.H.; Judge, L.M.; Yoo, J.; Huang, M.; Nguyen, T.D.; Lizarraga, P.P.; So, P.-L.; Conklin, B.R. Isolation of single-base genome-edited human iPS cells without antibiotic selection. Nat. Methods 2014, 11, 291–293. [Google Scholar] [CrossRef] [PubMed]
  20. Yusa, K.; Rashid, S.T.; Strick-Marchand, H.; Varela, I.; Liu, P.-Q.; Paschon, D.E.; Miranda, E.; Ordóñez, A.; Hannan, N.R.F.; Rouhani, F.J.; et al. Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells. Nature 2011, 478, 391–394. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  21. Sun, N.; Zhao, H. Seamless correction of the sickle cell disease mutation of the HBB gene in human induced pluripotent stem cells using TALENs. Biotechnol. Bioeng. 2014, 111, 1048–1053. [Google Scholar] [CrossRef] [PubMed]
  22. Gabriel, R.; Lombardo, A.; Arens, A.; Miller, J.C.; Genovese, P.; Kaeppel, C.; Nowrouzi, A.; Bartholomae, C.C.; Wang, J.; Friedman, G.; et al. An unbiased genome-wide analysis of zinc-finger nuclease specificity. Nat. Biotechnol. 2011, 29, 816–823. [Google Scholar] [CrossRef] [PubMed]
  23. Klug, A. The Discovery of zinc fingers and their applications in gene regulation and genome manipulation. Annu. Rev. Biochem. 2010, 79, 213–231. [Google Scholar] [CrossRef] [PubMed]
  24. Joung, J.K.; Sander, J.D. TALENs: A widely applicable technology for targeted genome editing. Nat. Rev. Mol. Cell Biol. 2013, 14, 49–55. [Google Scholar] [CrossRef] [PubMed]
  25. Jiang, W.; Bikard, D.; Cox, D.; Zhang, F.; Marraffini, L.A. RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nat. Biotechnol. 2013, 31, 233–239. [Google Scholar] [CrossRef] [PubMed]
  26. Gupta, A.; Meng, X.; Zhu, L.J.; Lawson, N.D.; Wolfe, S.A. Zinc finger protein-dependent and -independent contributions to the in vivo off-target activity of zinc finger nucleases. Nucleic Acids Res. 2010, 16, 17589–17610. [Google Scholar] [CrossRef] [PubMed]
  27. Guilinger, J.P.; Pattanayak, V.; Reyon, D.; Tsai, S.Q.; Sander, J.D.; Joung, J.K.; Liu, D.R. Broad specificity profiling of TALENs results in engineered nucleases with improved DNA-cleavage specificity. Nat. Methods 2014, 1–91. [Google Scholar] [CrossRef] [PubMed]
  28. Wang, H.; Hu, Y.C.; Markoulaki, S.; Welstead, G.G.; Cheng, A.W.; Shivalila, C.S.; Pyntikova, T.; Dadon, D.B.; Voytas, D.F.; Bogdanove, A.J.; et al. TALEN-mediated editing of the mouse Y chromosome. Nat. Biotechnol. 2013, 31, 530–532. [Google Scholar] [CrossRef] [PubMed]
  29. Yusa, K. Seamless genome editing in human pluripotent stem cells using custom endonuclease-based gene targeting and the piggyBac transposon. Nat. Protoc. 2013, 8, 2061–2078. [Google Scholar] [CrossRef] [PubMed]
  30. Nagy, A. Cre recombinase: the universal reagent for genome tailoring. Genesis 2000, 26, 99–109. [Google Scholar] [CrossRef]
  31. Semprini, S.; Troup, T.J.; Kotelevtseva, N.; King, K.; Davis, J.R.E.; Mullins, L.J.; Chapman, K.E.; Dunbar, D.R.; Mullins, J.J. Cryptic loxP sites in mammalian genomes: Genome-wide distribution and relevance for the efficiency of BAC/PAC recombineering techniques. Nucleic Acids Res. 2007, 35, 1402–1410. [Google Scholar] [CrossRef] [PubMed]
  32. Harno, E.; Cottrell, E.C.; White, A. Metabolic Pitfalls of CNS Cre-Based Technology. Cell Metab. 2013, 18, 21–28. [Google Scholar] [CrossRef] [PubMed]
  33. Fraser, M.J.; Ciszczon, T.; Elick, T.; Bauser, C. Precise excision of TTAA-specific lepidopteran transposons piggyBac (IFP2) and tagalong (TFP3) from the baculovirus genome in cell lines from two species of Lepidoptera. Insect Mol. Biol. 1996, 5, 141–151. [Google Scholar] [CrossRef] [PubMed]
  34. Wang, W.; Lin, C.; Lu, D.; Ning, Z.; Cox, T.; Melvin, D.; Wang, X.; Bradley, A.; Liu, P. Chromosomal transposition of PiggyBac in mouse embryonic stem cells. Proc. Natl. Acad. Sci. USA 2008, 105, 9290–9295. [Google Scholar] [CrossRef] [PubMed]
  35. Lacoste, A.; Berenshteyn, F.; Brivanlou, A.H. An efficient and reversible transposable system for gene delivery and lineage-specific differentiation in human embryonic stem cells. Cell Stem Cell 2009, 5, 332–342. [Google Scholar] [CrossRef] [PubMed]
  36. Nakade, S.; Tsubota, T.; Sakane, Y.; Kume, S.; Sakamoto, N.; Obara, M.; Daimon, T.; Sezutsu, H.; Yamamoto, T.; Sakuma, T.; et al. Microhomology-mediated end-joining-dependent integration of donor DNA in cells and animals using TALENs and CRISPR/Cas9. Nat. Commun. 2014, 5, 5560. [Google Scholar] [CrossRef] [PubMed]
  37. Miller, J.C.; Holmes, M.C.; Wang, J.; Guschin, D.Y.; Lee, Y.-L.; Rupniewski, I.; Beausejour, C.M.; Waite, A.J.; Wang, N.S.; Kim, K.A.; et al. An improved zinc-finger nuclease architecture for highly specific genome editing. Nat. Biotechnol. 2007, 25, 778–785. [Google Scholar] [CrossRef] [PubMed]
  38. Szczepek, M.; Brondani, V.; Büchel, J.; Serrano, L.; Segal, D.J.; Cathomen, T. Structure-based redesign of the dimerization interface reduces the toxicity of zinc-finger nucleases. Nat. Biotechnol. 2007, 25, 786–793. [Google Scholar] [CrossRef] [PubMed]
  39. Doyon, Y.; Vo, T.D.; Mendel, M.C.; Greenberg, S.G.; Wang, J.; Xia, D.F.; Miller, J.C.; Urnov, F.D.; Gregory, P.D.; Holmes, M.C. Enhancing zinc-finger-nuclease activity with improved obligate heterodimeric architectures. Nat. Methods 2010, 8, 74–79. [Google Scholar] [CrossRef] [PubMed]
  40. Ran, F.A.; Hsu, P.D.; Lin, C.-Y.; Gootenberg, J.S.; Konermann, S.; Trevino, A.E.; Scott, D.A.; Inoue, A.; Matoba, S.; Zhang, Y.; et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 2013, 154, 1380–1389. [Google Scholar] [CrossRef] [PubMed]
  41. Ran, F.A.; Cong, L.; Yan, W.X.; Scott, D.A.; Gootenberg, J.S.; Kriz, A.J.; Zetsche, B.; Shalem, O.; Wu, X.; Makarova, K.S.; et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 2015, 520, 186–191. [Google Scholar] [CrossRef] [PubMed]
  42. Kleinstiver, B.P.; Prew, M.S.; Tsai, S.Q.; Topkar, V.V.; Nguyen, N.T.; Zheng, Z.; Gonzales, A.P.W.; Li, Z.; Peterson, R.T.; Yeh, J.-R.J.; et al. Engineered CRISPR-Cas9 nucleases with altered PAM specificities. Nature 2015, 523, 481–485. [Google Scholar] [CrossRef] [PubMed]
  43. Nishimasu, H.; Ran, F.A.; Hsu, P.D.; Konermann, S.; Shehata, S.I.; Dohmae, N.; Ishitani, R.; Zhang, F.; Nureki, O. Crystal structure of Cas9 in complex with guide RNA and target DNA. Cell 2014, 156, 935–949. [Google Scholar] [CrossRef] [PubMed]
  44. Anders, C.; Niewoehner, O.; Duerst, A.; Jinek, M. Structural basis of PAM-dependent target DNA recognition by the Cas9 endonuclease. Nature 2014, 513, 569–573. [Google Scholar] [CrossRef] [PubMed]

Share and Cite

MDPI and ACS Style

Ochiai, H. Single-Base Pair Genome Editing in Human Cells by Using Site-Specific Endonucleases. Int. J. Mol. Sci. 2015, 16, 21128-21137. https://doi.org/10.3390/ijms160921128

AMA Style

Ochiai H. Single-Base Pair Genome Editing in Human Cells by Using Site-Specific Endonucleases. International Journal of Molecular Sciences. 2015; 16(9):21128-21137. https://doi.org/10.3390/ijms160921128

Chicago/Turabian Style

Ochiai, Hiroshi. 2015. "Single-Base Pair Genome Editing in Human Cells by Using Site-Specific Endonucleases" International Journal of Molecular Sciences 16, no. 9: 21128-21137. https://doi.org/10.3390/ijms160921128

APA Style

Ochiai, H. (2015). Single-Base Pair Genome Editing in Human Cells by Using Site-Specific Endonucleases. International Journal of Molecular Sciences, 16(9), 21128-21137. https://doi.org/10.3390/ijms160921128

Article Metrics

Back to TopTop